Aprea Therapeutics, Inc. filed a Form D with the Securities and Exchange Commission on 2025-12-29.
Aprea Therapeutics, Inc. filed a Form D notice of an exempt securities offering with the SEC on December 29, 2025. The filing reports $3.06M sold. Its industry group is Biotechnology. It names Oren Gilad (Executive Officer, Director), John Hamill (Executive Officer), Richard Peters (Director) (SEC Form D, December 29, 2025).
Sell to companies like Aprea Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-12-29 · the record
Pitching, partnering or investing alongside them? See who really runs and owns Aprea Therapeutics, Inc.
Free to see. No signup.
More on the people and the money behind Aprea Therapeutics, Inc., from the filings we hold.
Maxim Group LLC received sales compensation on this raise and on 9 other raises we hold, nearest in date first:
Biotechnology raises by companies based in Pennsylvania, filed within 90 days of this one, largest first.
Get an email when Aprea Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when Aprea Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Aprea Therapeutics, Inc. →Get the full cited report on Aprea Therapeutics, Inc.
What the filing shows about Aprea Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Aprea Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
Saved here on this device in the meantime, so nothing is lost either way.
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
Order the Full Report on Aprea Therapeutics, Inc. See pricing
Trailing twelve months. 759 filings in Biotechnology, totalled by week. The dot is this raise, $3.06M, on the same scale — one filing against the whole group's total, so it sits low by construction.
Oren Gilad is named as Executive Officer and Director on the Form D that Aprea Therapeutics, Inc. filed with the SEC on 29 December 2025, one of 10 people that filing names.
John Hamill is named as Executive Officer on the Form D that Aprea Therapeutics, Inc. filed with the SEC on 29 December 2025, one of 10 people that filing names.
Richard Peters is named as Director on the Form D that Aprea Therapeutics, Inc. filed with the SEC on 29 December 2025, one of 10 people that filing names.
Jean-Pierre Bizzari is named as Director on the Form D that Aprea Therapeutics, Inc. filed with the SEC on 29 December 2025, one of 10 people that filing names.
Marc Duey is named as Director on the Form D that Aprea Therapeutics, Inc. filed with the SEC on 29 December 2025, one of 10 people that filing names.
Michael Grissinger is named as Director on the Form D that Aprea Therapeutics, Inc. filed with the SEC on 29 December 2025, one of 10 people that filing names.
Gabriela Gruia is named as Director on the Form D that Aprea Therapeutics, Inc. filed with the SEC on 29 December 2025, one of 10 people that filing names.
John Henneman is named as Director on the Form D that Aprea Therapeutics, Inc. filed with the SEC on 29 December 2025, one of 10 people that filing names.
Rifat Pamukcu is named as Director on the Form D that Aprea Therapeutics, Inc. filed with the SEC on 29 December 2025, one of 10 people that filing names.
Bernd Seizinger is named as Director on the Form D that Aprea Therapeutics, Inc. filed with the SEC on 29 December 2025, one of 10 people that filing names.
10 people named on the filing — 2 holding an executive role and 8 as directors only.
Named as of the 2025-12-29 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about Aprea Therapeutics, Inc.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Aprea Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Aprea Therapeutics, Inc. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist Aprea Therapeutics, Inc.You get an alert in MentionFox the next time this company shows up.
If you're behind Aprea Therapeutics, Inc.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov.
Each opens in a new tab, filled in for Aprea Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
On these lists: Biotech raises in Philadelphia
https://mentionfox.com/funding/aprea-therapeutics-inc-form-d-25000001